Better HIV antibodies may lead to new vaccine

accreditation
iStock
A method for developing antibodies with the ability to kill multiple strains of the human immunodeficiency virus (HIV) was announced by South African scientists working with US researchers.

A small number of HIV-infected people developed the antibodies, but are not helped by them because they are unable to kill the wide range of HIV, said National Institute of Communicable Diseases virology head Prof Lynn Morris.

Read: HIV antibody breakthrough

Broadly neutralising antibodies

"We need to understand how to make better antibodies to HIV. We can learn that from people who are already infected, because a small proportion of them [infected people] make these broadly neutralising antibodies," she told reporters in Johannesburg.

"There has been a lot of focus on the individuals that make this special type of antibodies. That information, we hope, is going to help us make a better vaccine to HIV."

A KwaZulu-Natal woman, identified in the research as CAP256, had responded to HIV infection by making the broadly neutralising antibodies.

The research team had identified these antibodies in her blood and duplicated them by cloning them in a laboratory.

A new vaccine

The cloned antibodies were then used in a series of experiments to clarify the pathway followed by CAP256's immune system to make the HIV-combating antibodies.

The identification and successful cloning of the antibodies had enabled researchers to make large quantities for further testing, similar to the way a medicine used to prevent or treat HIV would be tested.

"What we have to do now is to design a vaccine that is able to engage with the rare B-cells. If we are able to do that, we should be able to make a vaccine that will take months for people to develop the immunity against HIV," said Morris.

Read: Antibodies kill 88% of HIV types

Sometimes referred to as the body's army, antibodies are specialised cells produced by B-cells as a primary immune defence. They are used by the body for either treatment or prevention.

Morris said CAP256's antibodies would be used in a sequence of pre-clinical trials in monkeys, a process which could take years to prove their efficacy.

US vaccine research centre

If successful, the research would guide HIV vaccine development. The antibodies might also be used as treatment for HIV.

The research was primarily funded by the US vaccine research centre, and the science and technology department.

The scientists worked in the "Caprisa" consortium of Aids researchers, which included the University of KwaZulu-Natal, the University of the Witwatersrand, the National Institute of Communicable Diseases, the University of Cape Town, and Columbia University in the US.

Read more:

Motsoaledi lauds HIV discovery

Swarms of antibodies could control HIV

Scientists Find Clues to How the Body Fights Off HIV

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For only R75 per month, you have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today.
Subscribe to News24
Voting Booth
Have you entered our Health of the Nation survey?
Please select an option Oops! Something went wrong, please try again later.
Results
Yes
29% - 9754 votes
No
71% - 24035 votes
Vote